Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ACRX

AcelRx Pharmaceuticals (ACRX) Stock Price, News & Analysis

AcelRx Pharmaceuticals logo

About AcelRx Pharmaceuticals Stock (NASDAQ:ACRX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.49
$0.86
52-Week Range
N/A
Volume
243,500 shs
Average Volume
137,683 shs
Market Capitalization
$14.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ACRX Stock News Headlines

This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
See More Headlines

ACRX Stock Analysis - Frequently Asked Questions

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) announced its quarterly earnings results on Monday, November, 15th. The specialty pharmaceutical company reported ($1.40) EPS for the quarter, meeting analysts' consensus estimates of ($1.40). The specialty pharmaceutical company had revenue of $1.86 million for the quarter, compared to analysts' expectations of $1.20 million.

Shares of AcelRx Pharmaceuticals reverse split on the morning of Wednesday, October 26th 2022.The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Meta Platforms (META) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
11/15/2021
Today
8/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ACRX
CIK
1427925
Employees
19
Year Founded
2005

Profitability

EPS (Trailing Twelve Months)
($2.23)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$47.76 million
Net Margins
N/A
Pretax Margin
-3,711.25%
Return on Equity
-81.54%
Return on Assets
-46.02%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.04
Quick Ratio
4.04

Sales & Book Value

Annual Sales
$1.77 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.65 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
16,950,000
Free Float
16,443,000
Market Cap
$14.58 million
Optionable
Optionable
Beta
0.52

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:ACRX) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners